Kidtrayze (Zinc Chloride, Potassium Iodide, Sodium Selenite, Copper Chloride Dihydrate, Manganese Chloride Tetr)

Each component acts as a cofactor for specific enzymes. Zinc supports DNA synthesis, copper is essential for oxidase enzymes, iodine is required for thyroid hormone production, selenium contributes to antioxidant enzymes, and manganese participates in carbohydrate metabolism. Together they restore normal enzymatic activity and metabolic balance.

The dose of Kidtrayze is determined by the prescribing clinician based on the patient’s laboratory values, clinical condition and nutritional requirements. Only a qualified health professional should set the dosing regimen.

Kidtrayze may be used in pregnancy or lactation only when clearly indicated and when the potential benefits outweigh any possible risks. The prescriber should evaluate maternal and fetal needs and monitor trace element levels closely.

To order Kidtrayze, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Kidtrayze combines five essential trace elements in a single sterile intravenous formulation, reducing the need for multiple separate injections. Compared with single‑element products, it offers convenience and ensures balanced supplementation, but clinicians must still individualise dosing according to specific patient deficiencies.

Kidtrayze must be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the vial. Before use, inspect for particulate matter and ensure the solution is clear.

Kidtrayze is given by intravenous infusion, typically diluted in compatible IV fluids and administered over a controlled period as directed by the prescribing clinician. Administration should be performed by trained healthcare personnel in a setting equipped for monitoring infusion reactions.

Serious risks include anaphylactic reactions, severe hypotension, acute renal impairment, marked electrolyte disturbances, hemolysis and severe hepatic dysfunction. Immediate medical attention is required if any of these events occur during or after infusion.

Kidtrayze should be avoided in patients with known hypersensitivity to any of its components, in those receiving high‑dose chelating agents, and in individuals with uncontrolled severe renal or hepatic disease unless the benefits clearly outweigh the risks.